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Abstract
Cytokines, including TNFa and IL-1b , are central to the chronic inflammatory process and tissue damage that
characterises diseases such as rheumatoid arthritis. The mechanisms responsible for long-term generation of these molecules
are poorly understood. We have previously demonstrated impaired activity of Na,K-ATPase, a key enzyme regulating
intracellular cation levels, on rheumatoid mononuclear cells. Mimicking this ‘defect’ on normal mononuclear cells with
ouabain has been shown to induce TNFa and, in particular, IL-1b production, whereas IL-6 synthesis was suppressed. A
similar pattern of cytokine generation was noted when mononuclear cells were treated with the sodium ionophore,
monensin. Induction of cytokine production was related to up-regulation of the appropriate mRNA, although enhanced
secretion of processed IL-1b was also observed. The mechanism underlying these cellular responses appears to involve
sodiumrcalcium exchange across the cell membrane. Impaired Na,K-ATPase activity might promote pro-inflammatory
cytokine secretion in patients with rheumatoid arthritis.
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1. Introduction
Cytokines are potent regulators of cell function
relevant to virtually all aspects of tissue physiology
and pathology. Chronic inflammation, such as exem-
 .plified by the disease rheumatoid arthritis RA , is
one process in which a wide range of cytokines,
including IL-1, TNFa and IL-6, are critically in-
w xvolved in promoting tissue injury 1 . Reviews of the
w xbiological properties of these cytokines 2–5 , and in
particular of IL-1 and TNFa , show a close correla-
tion with observed changes in the rheumatoid joint.
) Corresponding author. Fax: q44 1225 826114. E-mail:
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Numerous studies have demonstrated local synthesis
w x w x w xof IL-1a and b 6–8 , TNFa 6,9 and IL-6 6,10 in
this tissue. Recently, both chimeric anti-TNFa mono-
w x w xclonal antibody 11 and IL-1 receptor antagonist 12
have been shown to exert beneficial therapeutic ef-
fects in rheumatoid patients.
The mechanisms underlying the long-term genera-
tion of pro-inflammatory cytokines within chronically
inflamed tissue are unclear, but are likely to be
complex and multifactorial. Little is known about the
functional consequences of biochemical changes oc-
curring within cells through exposure to the chronic
inflammatory process. Recent observations have iden-
tified an impairment of Na,K-ATPase activity the
.sodium pump, EC 3.6.1.37 in rheumatoid erythro-
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w xcyte membranes 13 , and we have shown similar
results in studies of peripheral blood mononuclear
 . w xcells MNC 14 . The Na,K-ATPase is the key ion-
motive enzyme in all eukaryotic cells, pumping
potassium into and sodium out of the cell at the
expense of hydrolysing ATP and, through secondary
cation exchangers and antiporters e.g. NarCa,
.NarH , effectively controlling intracellular calcium
w xand other cation levels 15 . The electrogenic action
of the pump helps to maintain the cell’s membrane
potential, and the ion gradients generated are used to
regulate many aspects of cell function, including
glucose and aminoacid transport, osmotic balance and
cell volume. The enzyme is specifically inhibited by
ouabain and other cardiac glycosides. Given its vital
role in regulating intracellular cation levels and the
importance of such cations in cell signalling path-
ways, it seemed likely that impairment of the Na,K-
ATPase activity would have functional consequences
in MNC that might be relevant to the chronic inflam-
matory process. In this report, nanomolar concentra-
tions of ouabain have been shown to exert marked
but differential effects on cytokine generation by
healthy MNC.
2. Materials and methods
2.1. MNC preparation
MNC from peripheral blood of healthy volunteers
were isolated by density gradient centrifugation on
Lymphoprep densitys1.077 grml, Oxoid, Bristol,
.UK . After washing in PBS, the cells were suspended
at the required density in RPMI 1640 medium con-
taining glutamine, penicillin-streptomycin and 5%
vrv heat-inactivated fetal calf serum Life Technolo-
.gies, Paisley, Scotland, UK .
2.2. Induction and assay of cytokine proteins
Mononuclear cells were incubated at 378C in
polypropylene tubes Falcon, Becton Dickinson, Ox-
.ford, UK to minimise false positive cytokine profiles
due to adherence activation and were stimulated with
 .ouabain Sigma, Poole, Dorset, UK , a specific
 .Na,K-ATPase inhibitor, monensin Sigma , a sodium
 .ionophore, or the calcium ionophore A23187 Sigma
over titration ranges of 1 nM to 10 mM and time
courses up to 24 h. Some cultures also contained
 .3,4-dichlorobenzamil 0.3–30 mM, DCB , a selective
w xsodiumrcalcium exchange inhibitor 16 . Unless
stated otherwise, all incubations were carried out in
RPMI 1640 medium supplemented with 5% vrv
heat-inactivated FCS. Supernatants were harvested by
centrifugation at 1500 rpm for 5 minutes at room
temperature and careful aspiration from the cell pel-
lets. These supernatants were then stored at y208C
until cytokine content was quantified by immunoas-
 .say Medgenix, High Wycombe, Bucks, UK follow-
ing the instructions supplied with the kits.
2.3. Induction and detection of cytokine messenger
RNAs
Levels of mRNA encoding the TNFa , IL-1b and
IL-6 proteins were determined by Northern blot anal-
w x w xysis 17 of total cellular RNA 18 using cDNA
oligonucleotide probes labelled by random sequence
hexanucleotide priming using the Klenow fragment
w 32 x and a- P dATP Multiprime, Promega, Southamp-
.ton, UK . IL-1b mRNA was detected using a 320 bp
w xEcoRI-PstI fragment from pGem1 IL-1b 19 , and
the cDNA probe for TNFa was a 1200 bp molecule
w xderived from PAT-153 using PstI 20 . IL-6 mRNA
was identified using a 300 bp Sal I-EcoRI fragment
w xfrom pSP-64 21 , and the control probe used was
glyceraldehyde-3-phosphate dehydrogenase
 .GAPDH cDNA, a 1000 bp molecule derived from
w xpG3PCR-4 using BamHI 22 .
2.4. Determination of intracellular IL-1b by flow
cytometry
Total intracellular IL-1b 31 kDa precursor plus
.17 kDa mature form was quantified in control and
ouabain-stimulated MNC by flow cytometry Becton
Dickinson FacStar Plus with air-cooled argon ion
.laser . Cells were fixed and permeabilised with para-
w xformaldehyde and saponin 23 . Specific protein was
detected using a primary mouse monoclonal antibody
 .Genzyme Diagnostics, West Malling, Kent, UK and
secondary FITC-conjugated anti-mouse IgG reagents
 .Sigma . Control replicates included both an irrele-
vant isotype-matched primary antibody, and sec-
ondary antibody alone.
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3. Results
From measurements of 3H-ouabain binding and
functional enzyme inhibition experiments data not
.shown , it was estimated that the degree of Na,K-
ATPase inhibition detected on rheumatoid MNC could
be reproduced by incubating normal cells with
ouabain concentrations of 1–3=10y8 M. Accord-
ingly, functional studies involving time courses and
dose response curves to ouabain were performed
around this range. The most dramatic outcome of
inhibiting Na,K-ATPase was to increase production
of IL-1b from low levels to a mean value of over 10
ngr106 cells after 24 h. The results shown in Fig. 1A
indicate that production of IL-1b was just detectable
after 2 h incubation at 378C with the optimal concen-
 .tration of ouabain 100 nM , and reached a maximum
after 12 h culture. This represents extracellular secre-
tion of mature 17 kD IL-1b , since this is the only
molecular species detected by the immunoassay kit
 .used Medgenix . The induction of TNFa production
was slightly faster than that of IL-1b , being apparent
within 1 h and peaking after 4 h incubation with
 .ouabain Fig. 1B . However, production of TNFa
was consistently up to ten-fold less than that of
IL-1b. Production of IL-6 was, in most cases, readily
 .detectable in unstimulated MNC Fig. 1C , increasing
with time over 24 h. In the presence of ouabain, IL-6
production paralleled that in control cultures for the
first 2 h of incubation, and then ceased completely.
This argues against the notion that ouabain might be
enhancing cytokine secretion non-specifically, either
by overt toxicity or some other mechanism. This
pattern of results was unaffected by adding polymyxin
 .B up to 10 mM to the cultures to inactivate any
endotoxin present. In contrast, preincubating the MNC
with an inhibitor of protein synthesis, cycloheximide
 .10 mM for 12 h , abolished all detectable cytokine
synthesis in response to subsequent stimulation by
 .ouabain data not shown .
Since the initial biochemical change within
ouabain-treated cells will be an increase in intra-
cellular sodium ion concentration, functional out-
comes mediated by ouabain might also occur in cells
responding to the sodium ionophore monensin. In-
deed, the pattern of cytokine responses to this com-
pound was very similar to that observed for ouabain
 .Fig. 2 . Both induced a marked increase in the
Fig. 1. Time course of cytokine induction in healthy MNC by
 .ouabain 100 nM . Data are presented as mean secreted protein
levels qS.D. of 4–6 individual experiments. Filled bars are
results from control cultures, hatched bars are plus ouabain. Panel
A, IL-1b ; Panel B, TNFa ; Panel C, IL-6.
production of IL-1b and TNFa by MNC, with a fall
in the generation of IL-6. For comparative purposes,
cytokine production was determined in MNC re-
sponding to the calcium ionophore A23187. This
compound also caused induction of IL-1b and TNFa
 .synthesis but suppressed IL-6 secretion Fig. 2 . The
similarity between the patterns of cytokine produc-
tion by MNC responding to ouabain, monensin and
A23187 indicated that all three reagents could be
functioning through increasing intracellular calcium
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ion concentrations. To test this, MNC were stimu-
lated with ouabain in the presence of 3,4-dichlorobe-
 .nzam il D CB , a selective inhibitor of
Fig. 2. Dose response of cytokine induction in healthy MNC
incubated for 24 h with ouabain, monensin or A23187. Data are
presented as percentage cytokine secretion relative to control
 .unstimulated cultures s100% and represent meanqS.D. of
4–7 experiments. Absolute levels of cytokine production in
control cultures were as illustrated in Figure 1. Filled bars are
results from ouabain-, close hatched bars are from monensin- and
light hatched bars are from A23187-stimulated MNC. Panel A,
IL-1b , Panel B, TNFa , Panel C, IL-6.
 .Fig. 3. Effect of 3,4-dichlorobenzamil DCB on IL-1b and
TNFa production by healthy MNC incubated for 24 h with
 .ouabain 100 nM . Data are the mean of 3 experiments and
represent % cytokine productionqS.D. relative to values in the
 .absence of DCB s100% . Mean absolute cytokine production
in control ouabain-stimulated cultures was 7000 pgrml IL-1b
and 1680 pgrml TNFa .
w xsodiumrcalcium exchange 16 . These experiments
show a dose-dependent inhibition of IL-1b and TNFa
 .production by the ouabain-stimulated MNC Fig. 3 .
In all experiments, cell viability as measured by
trypan blue exclusion was unaffected by any of the
 .compounds )95% at 24 h except at the highest
 .concentrations tested viability 75–85% .
The time-course of the ouabain-mediated changes
in cytokine production was consistent with an effect
on mRNA transcription, and direct evidence support-
ing this was obtained by Northern blot analysis of
total cellular RNA extracted from control and
ouabain-treated MNC. A representative experiment
illustrating dose-dependent responses to ouabain in
cells treated for 2 h at 378C is shown in Fig. 4. The
data indicate that some IL-1b mRNA is detectable
with only 1 nM ouabain, but maximum induction of
IL-1b mRNA was obtained at a concentration of 100
nM. The induction of TNFa mRNA showed a similar
response profile, with maximal levels being detected
at 100 nM ouabain. Significant expression of IL-6
mRNA was detected in control cultures, which was
 .markedly reduced by low 1–10 nM ouabain con-
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Fig. 4. Effect of ouabain concentration on cytokine mRNA
induction in healthy MNC incubated for 2 h at 378C. Data from
an individual cell sample are shown, which is representative of 5
separate experiments. Detection of GAPDH mRNA was under-
taken to check for gel loading errors.
centrations. Interestingly, some IL-6 mRNA re-
mained in the cells even in the presence of high
ouabain levels.
In addition to the above effects on transcription of
cytokine mRNAs, ouabain was also investigated as a
potential modulator of the secretion of IL-1b follow-
ing processing from its intracellular 31 kDa precur-
sor. Data in Table 1 demonstrate a dose-dependent
decrease both in the proportion of cells staining
 .positive for intracellular IL-1b 31 kDa plus 17 kDa
and in the Mean Fluorescence intensity of those
Table 1
Effect of ouabain on levels of intracellular IL-1b after 24 h
incubation
 .Stimulus % positive cells MFI positive cells
None 25.0"4.1 543"60
y9Ouabain: 10 M 17.0"5.1 432"57
y810 M 4.0"1.0 297"47
y710 M 2.0"0.4 286"34
Data are presented as mean"S.D. of 3 experiments, showing %
positive cells staining for intracellular IL-1b and the mean fluo-
 .rescence intensity MFI of those positive cells.
positive cells following 24 h incubation with increas-
ing concentrations of ouabain. Levels of secreted
IL-1b showed a concomitant increase over the same
dose range.
4. Discussion
Incubation of normal MNC with non-toxic,
nanomolar concentrations of ouabain caused both a
marked stimulation of TNFa , and more especially
IL-1b , production, but suppression of IL-6 synthesis.
An earlier report has also demonstrated stimulation of
w xIL-1b production by ouabain 24 , and our data are
consistent with other reports showing enhanced IL-1b
processing and secretion following an induced fall in
w xintracellular potassium levels 25,26 , or following
w xincreases in intracellular sodium levels 27 . A
sodium-dependent modulation of TNFa production
w xby human monocytes has also been reported 28 . The
major action of ouabain on cytokine production by
MNC in this study is clearly mediated at the gene
level through modulating transcription of the relevant
mRNAs. The time course of these effects suggested
that mRNA stability and half-life were not markedly
influenced by inhibiting Na,K-ATPase data not
.shown , although direct measurements of these pa-
rameters were not performed. The time courses and
concentration dependency of changes in cytokine
mRNA expression were in close agreement with the
measurements of cytokine protein production. Up-
regulation of TNFa mRNA occurred first, with IL-1b
mRNA being induced slightly more slowly. Perhaps
surprisingly, it was possible to demonstrate the ap-
pearance of IL-6 mRNA in the ouabain-stimulated
MNC, although no secreted protein product was de-
tectable following the initial 2 h of the culture period.
This requires further investigation of events down-
stream from transcription, such as processing and
secretion of IL-6 protein, which may be modulated
by inhibition of Na,K-ATPase.
The significance of these acute observations of
ouabain-treated healthy MNC to the chronic over-
production of pro-inflammatory cytokines in rheuma-
toid synovial tissue remains unproven. It is clear from
data generated in both functional and ligand-binding
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assays that Na,K-ATPase enzyme activity is de-
pressed on rheumatoid peripheral blood MNC. These
observations support other results showing a similar
w x‘defect’ on rheumatoid erythrocytes 13 and suggest
that this biochemical abnormality may be detectable
in a wide range of cells from these patients. A more
detailed examination of cation-dependent biochem-
istry in rheumatoid cells would seem to be justified
given the profound effects of inhibiting Na,K-ATPase
on cytokine production by healthy MNC. The
nanomolar concentrations of ouabain achieving these
effects in vitro induce a degree of Na,K-ATPase
inhibition that is similar to the depressed enzyme
activity on rheumatoid MNC observed ex vivo. Bio-
chemical changes following impairment of the sodium
pump include a rise in intracellular sodium and,
through sodium-calcium exchange, calcium ion con-
centrations. Data presented in this report strongly
suggest that the effects on cytokine production of
inhibiting the Na,K-ATPase are mediated through
changes in intracellular calcium ion concentration.
DCB, a selective sodium-calcium exchange inhibitor
w x16 suppressed IL-1b and TNFa generation with an
IC of approximately 3 mM. This potency is similar50
to that observed for DCB-mediated suppression of T
w xcell proliferation and IL-2 secretion 29 . Increased
levels of sodium ions have been measured in rheuma-
w xtoid erythrocytes 13 , and elevated intracellular cal-
cium levels have been determined in rheumatoid red
w xblood cells and granulocytes 30 . Further studies are
justified to ascertain the significance of this biochem-
ical abnormality as a contributor to cytokine-media-
ted tissue damage in rheumatoid joints.
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